ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Practices treating 19 or more CML patients were more likely to document the palpable spleen size (66.5 vs. 33.5%), assess a specific risk score (54.7 vs. 30.6%) and less likely to perform an ABL-Kinase domain mutation analysis (18.6 vs. 28.8%) at diagnosis.